Carbamazepine Extended-Release Tablets and Mifepristone Tablets (For Ending Early Pregnancy)
Determining the interaction of Carbamazepine Extended-Release Tablets and Mifepristone Tablets (For Ending Early Pregnancy) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using carBAMazepine together with miFEPRIStone can alter the blood levels and effects of both medications. Specifically, miFEPRIStone levels may decrease, which may make the medication less effective. At the same time, carBAMazepine levels may increase. Contact your doctor if your condition changes or you experience increased side effects. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration of mifepristone with a drug that is both a substrate as well as inducer of CYP450 3A4 may result in decreased plasma concentrations of mifepristone and increased plasma concentrations of the other drug. Mifepristone itself is a substrate and inhibitor of CYP450 3A4. Theoretically, mifepristone may inhibit metabolism of the coadministered drug while its own metabolism may be induced by the coadministered drug.
MANAGEMENT: When a drug that is both a substrate as well as inducer of CYP450 3A4 is coadministered with mifepristone, the possibility of diminished therapeutic response to mifepristone should be considered. In addition, clinical and/or laboratory monitoring for potentially increased pharmacologic effects of the concomitant drug may be appropriate. Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).
- "Product Information. Mifeprex (mifepristone)" Danco Laboratories, New York, NY.
- He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7
Generic Name: carbamazepine
Brand name: Carbatrol, Epitol, Equetro, Tegretol, Tegretol XR, Tegretol, Tegretol XR
Synonyms: Carbamazepine, CarBAMazepine
Generic Name: mifepristone
Brand name: Korlym, Mifeprex
Synonyms: Mifepristone
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Carbamazepine Extended-Release Tablets-Mifepristone Tablets (For High Blood Sugar)
- Carbamazepine Extended-Release Tablets-Migalastat
- Carbamazepine Extended-Release Tablets-Migalastat Hydrochloride
- Carbamazepine Extended-Release Tablets-Migergot
- Carbamazepine Extended-Release Tablets-Migergot Suppository
- Carbamazepine Extended-Release Tablets-Miglitol
- Mifepristone Tablets (For Ending Early Pregnancy)-Carbamazepine Intravenous
- Mifepristone Tablets (For Ending Early Pregnancy)-Carbamazepine Oral Suspension
- Mifepristone Tablets (For Ending Early Pregnancy)-Carbamazepine Tablets
- Mifepristone Tablets (For Ending Early Pregnancy)-Carbaphen 12
- Mifepristone Tablets (For Ending Early Pregnancy)-Carbaphen CH
- Mifepristone Tablets (For Ending Early Pregnancy)-Carbaphen Ped CH